OGEN

Oragenics, Inc.

Oragenics, Inc. (OGEN) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 14 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D-
Factor Score 1.0 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.0
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -34.0%
Price Return 12M -69.0%
Catalyst Signal 0.00
Market Cap $1.6M
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held C- for 14 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C+ (2.5) D- (1.0) D+ (1.8) C+ (2.6) C- (2.1)
2026-11-06 C+ (2.5) C+ (2.5) D- (1.0) D+ (1.8) C+ (2.7) C- (2.1)
2026-10-30 C+ (2.5) C+ (2.5) D- (1.0) C- (1.9) C+ (2.7) C- (2.1)
2026-10-23 C+ (2.5) C+ (2.5) D- (1.0) D+ (1.8) C+ (2.6) C- (2.1)
2026-10-16 C+ (2.5) C+ (2.5) D- (1.0) D+ (1.8) C+ (2.6) C- (2.1)
Page 1 of 3